NCCN gives strong endorsement for sipuleucel-T

The National Comprehensive Cancer Network has updated its prostate cancer management guidelines to give a category 1 recommendation for clinical use of sipuleucel-T (Provenge) in the treatment of selected patients. … READ MORE …

Active surveillance for prostate cancer: an NCCN update

In a long media release today, the National Comprehensive Cancer Network (NCCN) encapsulated a presentation at the NCCN’s 15th Annual Conference by Dr. James L. Mohler, in which he discussed the role of active surveillance and other treatment options recommended in the recently updated NCCN Guidelines™ for Prostate Cancer. … READ MORE …

Clinicians’ opinions on active surveillance and the new NCCN guidelines

Last week we reported on the new NCCN guidance on prostate cancer management, including the heavy emphasis on active surveillance as a first-line treatment option for as many as 40 percent of men newly diagnosed with prostate cancer. Today a new article on Medscape also takes up this issue, with views from a select group of physicians on issues that relate to the implementation of this new guidance.

NCCN updates prostate cancer management guidance

In a media release issued earlier today, the National Comprehensive Cancer Network (NCCN) has announced updates to the NCCN Clinical Practice Guidelines for Oncology™ for Prostate Cancer, and has placed a new emphasis on the value of active surveillance in management of men with low and very low risk of clinically significant disease. … READ MORE …